

West Virginia Medicaid Drug Utilization Review Board Minutes

November 18, 2020

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

K.C. Lovin, PA-C, Chair
Christopher Terpening, PharmD, PhD, Vice Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Myra Chiang, MD
Kate Forman, PharmD
Phillip Galapon, MD
David Gloss, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS

Members Absent:

none

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Priya Shah, PharmD, Drug Utilization Review Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy Operations Manager
Gail Goodnight, Rebate Manager
Doug Sorvig, Data Analyst

Contract Staff:

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)
Robert Stanton, PharmD, Marshall University
Kim Broedel-Zaugg, RPh, PhD, Marshall University
Jon Willis, Marshall University
Eric Sears, RPh, Gainwell (DXC)
Jacqueline Hedlund, MD, Change Healthcare
Ryan Fell, PharmD, Change Healthcare

I. INTRODUCTIONS

- a. Christopher Terpening, Vice Chair, welcomed everyone to the Board meeting at 4:05 pm EDT. The DUR Board introduced themselves.

- II. **ARRPOVAL OF MINUTES FROM September 23, 2020 2020 DUR BOARD MEETING**
 - a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

- III. **OLD BUSINESS**
 - none

- IV. **NEW BUSINESS**
 - a. **Speakers**
 - i. none
 - b. **Updates from October 28th, 2020 P & T Committee Meeting**
 - i. Ryan Fell presented the updates from the October 28, 2020 P & T meeting for board review. No changes were requested. Approved as presented
 - c. **PDL Prior Authorization Criteria. Attachment A**
 - i. **Linzess 72 mcg, Zelnorm:** approved as amended
 - ii. **Spravato:** approved as presented
 - iii. **Epidiolex:** approved as presented
 - iv. **VMAT 2 Inhibitors:** approved as amended. Request to revisit next meeting**
 - v. **Benlysta:** approved as amended
 - vi. **Cytokine/CAM antagonists - Xeljanz:** approved as presented
 - vii. **MABS/ Anti IL/IgE:** approved as presented
 - viii. **Onfi/Diacomit:** approved as presented
 - ix. **Farxiga/ SGLT-2 Inhibitor:** approved as amended
 - x. **Nexletol, Nexlizet:** approved as amended
 - xi. **CGRP receptor antagonists (prophylaxis):** approved as presented

- V. **REPORTS – 3rd Quarter 2020**
 - a. **DXC Quarterly Report:** Mr. Sears presented an overview of the 2020 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
 - b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the Third Quarter of 2020. Attachment C
 - c. **Marshall University Coalition:** Dr. Stanton reported on the progress of retro DUR, the lock in program, and the number of letters sent/returned. Attachment D

- VI. **OTHER BUSINESS**
 - a. None

- VII. **NEXT MEETING AND ADJOURNMENT**
- VIII.
 - a. The meeting concluded at 5:43 pm EDT.
 - b. The next meeting will be February 24, 2021 from 4:00pm to 6:00pm virtually.